ContraFect Võlakoormus 2024

Mis teeb ContraFect?

The company ContraFect Corp was founded in 2008 by the renowned immunologist Dr. Robert Nowinski, with the aim of developing groundbreaking therapies for the treatment of infectious diseases. The company is a biopharmaceutical company focused on the development of antibiotic alternatives to be effective against bacteria that have become resistant to traditional antibiotics. The business model of ContraFect Corp is based on an innovative approach that harnesses the body's immune system defenses. Specifically, artificial proteins are developed to combat bacterial infections. These proteins are called "lysins." They work by selectively targeting specific bacterial cells, causing them to dissolve and die. ContraFect Corp is divided into various divisions, each specializing in a specific area of infection control. One division is "Lysin Discovery and Development," which focuses on the discovery of new lysins to combat bacteria. Another important division is "Research and Development," which aims to develop new therapies for the treatment of bacterial infections. The company also has specialized programs for treating specific bacterial infections such as cystic fibrosis. The company has developed a range of products that can be used to treat infectious diseases. The most important product of ContraFect Corp is CF-301, a lysin developed against Staphylococcus aureus - better known as "MRSA" or "hospital-acquired infection." This is an extremely dangerous strain of bacteria that conventional antibiotics increasingly show no effect against. The drug has shown promising results in clinical trials and is currently in Phase 3 of clinical development, nearing approval by the US Food and Drug Administration (FDA). Overall, ContraFect Corp has developed a variety of lysins that are effective against different types of bacteria. These lysins are administered in the form of injections or inhalers for rapid effect. In addition to the treatment of infectious diseases, ContraFect Corp also has a promising program in the early stages of research for the treatment of cystic fibrosis. ContraFect Corp has emerged as one of the leading companies in the field of antibiotic alternatives. The company is persistently working to develop new and innovative treatments to minimize the risks of antibiotic resistance. The company employs state-of-the-art technologies to ensure the effectiveness and safety of its products. Thanks to significant investments and promising results in clinical trials, the future of ContraFect Corp seems very promising. ContraFect ist eines der beliebtesten Unternehmen auf Eulerpool.com.